ARCA biopharma FY EPS $(0.69) Up From $(1.39) YoY; Cash & Cash Equivalents Of $42.4M Sufficient To Fund Its Operations Through The Middle Of 2024
ARCA biopharma (NASDAQ:ABIO) reported quarterly losses of $(0.69) per share. This is a 50.36 percent increase over losses of $(1.39) per share from the same period last year.